The insulin receptor substrate (IRS) proteins are cytoplasmic adaptors that organize signaling complexes downstream of activated cell surface receptors. Here, we show that IRS-1 and IRS-2, despite significant homology, play critical, yet distinct functions in breast cancer and we identify specific signaling pathways that are influenced by IRS-1 using the Polyoma Virus 
Introduction
The insulin receptor substrate (IRS) proteins are cytoplasmic docking proteins that function as essential signaling intermediates downstream of activated cell surface receptors including the insulin, Insulin-Like Growth Factor-1 (IGF-1), prolactin, growth hormone (GH), and vascular endothelial growth factor (VEGF) receptors, members of the integrin receptor family and select cytokine receptors (38, 68, 70, 78, 81, 85) . The IRS proteins are recruited to receptors through PH and PTB domains in their N-termini and mediate their functions by organizing signaling complexes at sites of receptor activation (81) . Upon binding they are phosphorylated on tyrosine residues in their C-termini, creating multiple phosphotyrosine 80 binding motifs that recruit downstream effectors including phosphatidylinositol 3-kinase, Grb-2, Fyn and Shp-2 to initiate intracellular signaling cascades (81) . The IRS proteins were originally identified as substrates of the insulin receptor, and they have been predominantly studied for their role in metabolic signaling (81) . Although the IRS proteins are highly homologous, there is evidence for unique functions for each of the four IRS family members. Irs-1 null mice are born small, and remain runted throughout life, and these mice develop insulin resistance. However, Irs-1 null mice do not develop diabetes because they maintain normal numbers of pancreatic beta cells (3) . In contrast, Irs-2 null mice are normal size at birth, but exhibit brain defects and develop early-onset diabetes due to a combination of peripheral insulin resistance and beta-cell failure (66, 83, 84) . Irs-3 null mice are phenotypically normal, and Irs-4 null mice have mild 90 reproductive and insulin sensitivity defects (16, 42) .
IRS-1 and IRS-2 are the IRS family members that are expressed in normal mammary epithelial tissue, both in humans and mice, and in breast cancer (37, 52) .
To date, more is known regarding the role of IRS-2 in breast cancer than of IRS-1. The importance of IRS-2 for breast cancer progression was first suggested by the fact that the IGF-1 receptor no longer promotes mitogenesis, but it is still required for metastasis, in estrogen receptor negative (ER-)
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breast carcinoma cell lines which lack or have decreased IRS-1 expression, but retain IRS-2 expression (15) . In these cell lines that signal predominantly through IRS-2, IGF-1 stimulates breast carcinoma cell motility (6, 14, 33, 86) . IRS-2 is also an essential intermediate in the
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activation of phosphatidylinositol 3-kinase (PI3K) and promotion of breast carcinoma invasion by the α6β4-integrin receptor (70) . The most compelling data that support a critical role for IRS-2 in breast cancer were provided by our study that examined the impact of Irs-2 deficiency on the Polyoma Virus Middle-T (PyV-MT) mouse model of mammary tumor progression (52) . We found that Irs-2 deficient mice did not exhibit differences in mammary tumor onset or growth when compared to mice with a wild-type genetic background. However, they did exhibit significantly reduced rates of metastasis (52) . Mammary tumor cells derived from the PyV-MT::Irs2 -/-mice also exhibited attenuated invasion and cell survival. These findings not only highlighted the importance of IRS-2 for breast cancer progression, they also revealed that IRS-1
is not sufficient to promote metastasis.
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The inability of Irs-1 to compensate for the loss of Irs-2 in mammary tumor metastasis in vivo supports the hypothesis that IRS-1 functions in breast cancer in a manner distinct from IRS-2. However, the existing data on IRS-1, which were derived largely from studies on human breast carcinoma cell lines, are conflicting and have not provided definitive insight into the contribution of IRS-1 to breast cancer. For example, suppression of IRS-1 expression in ER+ breast carcinoma cell lines inhibits IGF-1-dependent proliferation and survival, suggesting that IRS-1 plays a positive role in breast cancer (9, 53) . However, ER-breast carcinoma cell lines, which express low levels of IRS-1, are more invasive and metastatic than ER+ cells (32, 70 ). In the current study, we examined rigorously the role of Irs-1 in mammary tumorigenesis and 120 progression and investigated the specific pathways that are influenced by Irs-1 function. Our data reveal that loss of Irs-1 expression stimulates metastatic spread significantly. The
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significance of our findings for human breast cancer is heightened considerably by our novel observation that Irs-1 is selectively inactivated in metastatic mammary tumors.
Materials and Methods
Mice: Female C57Bl/6, Irs1 +/-mice were generated previously and were bred for 10 generations into the FVB genetic background (3 ) were saved for further analysis. Genotyping was performed by PCR using oligonucleotides specific for the Irs-1 gene (5'-GCCAGGCACCAGCATCTTCG-3' and 5'-TGGCCGCTCCCGAATTCAAT-3'), the neomycin gene (5'-GCTACCCGTGATATTGCTGAAGAG-3'), and as described previously for the PyV-MT transgene (24) . PyV-MT::Irs2 -/-female mice were generated as described previously (52) .
Beginning at 15 days of age, the mice were palpated every 5 days to detect the onset of mammary tumor development. At 75, 80 or 85 days, the tumors were dissected and measured using calipers. Total tumor volume was determined using the following formula: volume =
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(4/3)(p)(1/2 x smaller diameter) 2 (1/2 x larger diameter). Portions of the tumors and the lungs were either snap frozen or fixed in 10% buffered formalin. Blood was also collected at the time of sacrifice (100µl) and spun at 1000 rpm for 10 min at 4°C to obtain serum.
To examine the ability of Irs-1 deficient PyV-MT mammary tumor cells to grow and metastasize in a wildtype-Irs genetic background, PyV-MT and PyV-MT::Irs1 -/-mammary tumor cells (2x10 6 ) were resuspended in Matrigel (50 µl) and injected into the number 3 and number 8 thoracic mammary glands of female nu/nu mice. At an equivalent tumor burden (tumor size
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6 determined using the formula: volume = width 2 x length/2), the tumors and lungs were dissected and portions of each were either snap frozen or fixed in 10% buffered formalin (50) . followed by incubation overnight at 4°C with primary antibodies. To detect endothelial cells, tissue sections were digested with N-p-tosyl-L-phenylalanyl chloromethyl ketone-trypsin (0.05%) for 28 minutes before incubating overnight at 4°C with rat anti-mouse CD31 (2.5 µg/ml; BD Biosciences). The primary antibodies were amplified with biotinylated anti-rat (CD31) or antirabbit (ERα) IgG (Vector Laboratories) and detected using the Vectastain Elite ABC reagent
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(Vector Laboratories) with 3,3'-diaminobenzidine (DAB) as the substrate. CD31 staining was quantitated using NIH Image 1.61 software. To detect apoptotic cells, tissue sections were stained using the ApopTag Plus Peroxidase In Situ Apoptosis Detection kit according to the manufacturer's instructions (Chemicon, Temecula, CA).
ELISA assays: VEGF-A protein was measured using the murine VEGF Quantikine ELISA kit (R&D Systems) according to the manufacturer's instructions.
Real-time quantitative PCR (RQ-PCR):
Total RNA was isolated from lung tissue and tumors using the RNeasy extraction kit (Qiagen). Quantitative analysis of gene expression was 170 obtained using the ABI 7300 Sequence Detection System and TaqMan one-step RT-PCR Master Mix Reagents (Applied Biosystem). PyV-MT mRNA was amplified using the following
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primers and probe: forward primer, 5'-AGCCCGATGACAGCATATCC-3'; reverse primer, 5'-GGTCTTGGTCGCTTTCTGGA-3'; Taqman probe, 5'-CGGACCCCCCCAGAACTCCTGT-3'.
Murine VEGF-A primer pairs and probe were obtained from Applied Biosystems. The transcript quantity in each RNA sample was normalized to that of GAPDH using the TaqMan PreDeveloped Assay Reagent for rodents (Applied Biosystems). 
Immunoprecipitation and immunoblotting:
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For immunoblotting, the filters were blocked for 1 h with a 50 mM Tris buffer, pH 7. 
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Cell lines, siRNA and transfections: PyV-MT mammary tumor cell lines were established as described previously (52) . siRNA oligonucleotides for Irs-1 and Irs-2 targeting were as follows:
NNUAACCGGUUUCGAAAGAGA (siIrs1 no. 1), NNAGCCGGUCCUCUCUUACUA (siIrs1 no. 
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Statistics: For the densitometric analyses of immunoblots, the results were compared using the shown) (38, 68, 70, 78, 81, 85) . We also assessed the expression of the β4 integrin subunit as a marker of the epithelial content of the tumors and found equivalent expression levels, supporting that the overall tumor/stromal ratios were not altered by the loss of Irs-1 (48) ( Loss of Irs-1 promotes mammary tumor metastasis in a cell autonomous manner. PyV-MT mammary tumors are characterized by a high incidence of lung metastasis (24) . To test our hypothesis that Irs-1 regulates mammary tumor metastasis, we microscopically screened five independent H&E stained sections of the lungs from each of the PyV-MT or PyV-MT::Irs1 -/-mice. and 4EBP1 were phosphorylated at significantly higher levels in the PyV-MT::Irs1 -/-tumors than in the PyV-MT tumors, confirming that mTor-dependent signaling is elevated in Irs-1 deficient tumors (Fig. 5 ). In addition, S6 phosphorylation was increased significantly in the PyV-MT::Irs1 -/-tumors, providing evidence for enhanced S6K activation (Fig. 5) .
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Results
Irs
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Cell survival is increased in Irs-1 deficient mammary tumors. In addition to its important role as a translational regulator, eIF4E has also been implicated in oncogenesis through its contribution to survival signaling (72, 80) . To determine if eIF4E activity was increased in PyV- Akt activity is regulated by phosphorylation on two key residues, serine-473 and threonine-308 370 (2, 63) . Both residues were phosphorylated at higher levels in PyV-MT::Irs1 -/-tumors relative to
PyV-MT tumors (Fig 6A) . In addition, phosphorylation of GSK-3β on serine-9, an Akt-dependent site, was also significantly increased, confirming that Akt activity was enhanced in Irs-1 deficient tumors ( In support of this mechanism, Irs-2 was more heavily tyrosine phosphorylated in the PyV-MT::Irs1 -/-tumors than in the PyV-MT tumors (Fig. 7A) . Importantly, the amount of p85 regulatory subunit of PI3K that co-immunoprecipitated with Irs-2 was significantly higher in PyV-MT::Irs1 -/-tumors, indicating that Irs-2-dependent PI3K activation was increased (p<0.05; Figs.
7A,D).
To investigate further the connection between Irs-1 and Irs-2 expression, and to consistently phosphorylated on all of the serine residues that we examined in the metastatic tumors (Fig. 8) . In contrast, serine phosphorylation of Irs-1 in the non-metastatic tumors was sporadic, and none of the serine residues were consistently phosphorylated in the tumors we examined. To determine the effect of serine phosphorylation on Irs-1 function in the metastatic tumors, Irs-1 tyrosine phosphorylation was assessed.
The level of Irs-1 tyrosine phosphorylation in the metastatic tumors was markedly lower than that observed for Irs-1 in the non-metastatic tumors, demonstrating that Irs-1 function was suppressed in metastatic tumors (Fig. 8) .
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Discussion
In this study, we demonstrate that mammary tumor metastasis is enhanced in the absence of Irs-1. Specifically, mammary tumor latency and growth were not altered in Irs A novel and unexpected finding from our study is that Irs-2 activity increased in Irs-1 deficient mammary tumors. This activation of Irs-2, as indicated by increased tyrosine phosphorylation and association with PI3K, was coincident with an enhanced activation of Akt and mTor. Knock-down of Irs-2 restored the activation of these signaling molecules to wildtype 450 levels, supporting that Irs-2 is responsible for their enhanced activation in the absence of Irs-1.
Our observed increase in Irs-2 function was not anticipated because activation of mTor signaling has been shown to inhibit IRS expression and function (18, 69) . Negative feedback regulation of the IRS proteins was first demonstrated in insulin-dependent signaling and this feedback pathway is essential for regulating insulin sensitivity and glucose homeostasis (1, 39, 74) . Serine phosphorylation of the IRS proteins by multiple kinases, including the mTordependent p70-S6 kinase, can interfere with their function by targeting these docking proteins
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for inactivation and/or proteasomal degradation (22) . Inactivation occurs either through inhibition of recruitment to upstream regulatory receptors or disruption of interactions with downstream effectors (22) . In tumors that arise from mutations in pathways that impede mTor 460 signaling, such as the TSC1 or TSC2 genes, p70-S6 kinase is constitutively active (27, 69) .
These tumors grow quite large, but rarely progress to invasive carcinoma because both IRS-1 and IRS-2 are degraded in response to S6 kinase-mediated phosphorylation (46, 69) . In contrast to the benign nature of the TSC1/2 mutant tumors, we observed that Irs-1 deficient tumors, which have increased mTor signaling, progress more rapidly to metastasis. We hypothesize that the reason for this discrepancy is that Irs-2 is resistant to negative feedback regulation, which leads to enhanced function in the Irs-1 deficient tumors.
The fact that Irs-2 activation is enhanced in Irs-1 deficient tumors that are more metastatic substantiates our previous findings that Irs-2 is a positive regulator of mammary activation and impacting tumor metastasis.
Our conclusion that IRS-1 impedes metastasis, which was obtained using Irs-1 deficient 500 mice, implies that mechanisms exist in tumors to suppress IRS expression or function to promote progression. Indeed, a major observation from our study is that Irs-1 is expressed in metastatic wild-type mammary tumors but that it is phosphorylated on serine residues and inactivated. This finding raises the novel hypothesis that IRS-1 functions as a metastasis suppressor in breast cancer. Taken together with our previous work showing that IRS-2 promotes metastasis, it appears that the IRS proteins are prime candidates as prognostic markers for breast cancer progression. Interestingly, however, neither IRS-1 nor IRS-2 have been identified as markers of tumor progression or metastasis by microarray analysis, supporting our conclusion that changes in IRS function occur primarily at the level of protein
expression or activation, and not through changes in gene expression. To date, IRS-2 protein 510 expression has not been evaluated in human breast tumors, and only a few studies have directly assessed IRS-1 protein expression. One study reported strong down-regulation of IRS-1 in grade 3, poorly differentiated breast tumors, confirming our prediction for a positive correlation between low IRS-1 and poor prognosis (64) . However, separate studies have reported that high IRS-1 expression is predictive of a greater incidence of recurrence and a decreased patient survival rate (36, 60) . A caveat to these latter reports that is highlighted by our own data is that overall expression of IRS-1 or IRS-2 may not reflect the activation status of these docking proteins, and IRS-1 may be expressed, but not active, in these tumors with a poor prognosis. In future studies, it will be important to identify specific serine or tyrosine phosphorylation events that can be used to assess functional activity of these proteins in tumors 520 to evaluate prognosis more accurately.
Our molecular analysis of Irs-1 deficient tumors revealed that they express significantly more VEGF-A than do wild-type tumors, and that VEGF-A is increased in the serum of Irsdeficient tumor bearing mice. These tumors also exhibited a significant increase in microvessel density, which is consistent with increased VEGF expression. The possibility that increased VEGF-A expression and microvessel density in response to loss of Irs-1 promote progression is supported by numerous studies on human breast tumors that have correlated these parameters with disease progression and negative outcome, as well as by recent transgenic studies in which over-expression of VEGF-A in the mammary gland resulted in increased tumor 530 metastasis in mice (12, 54, 65, 75) . VEGF contributes to metastasis in a paracrine manner, by promoting tumor angiogenesis, and also acts in an autocrine manner to support the survival of with poor prognosis for breast cancer patients (12, 19, 62) . Akt activation is positively associated with disease progression and occurs early, at the ductal carcinoma in situ (DCIS) stage, and persists throughout tumor development (7) . mTor and its downstream effector p70-S6 kinase are both expressed and activated at high levels in invasive human breast carcinomas, and both of these signaling molecules are associated with an increased risk for disease recurrence (7, 35, 76, 87) . Expression of the translation initiator eIF4E is also upregulated in human cancers, including breast, and it has been linked to metastasis (8, 58) . In the absence of Irs-1, mouse mammary tumors exhibit increased activity of all of these signaling molecules, confirming that at the molecular level, loss of Irs-1 closely mimics the progression of human breast cancer to metastatic disease.
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In summary, we have established that suppression of Irs-1 promotes mammary tumor metastasis and we provide evidence that Irs-1 is inactivated in metastatic tumors. Taken together with our previous study demonstrating that loss of Irs-2 impedes mammary tumor metastasis, we now have strong evidence that IRS-1 and IRS-2 play distinct roles in breast cancer metastasis. Our novel findings support the possibility that IRS activity, rather than expression, may be a valuable predictive indicator of metastasis in human breast cancer. 
